Machine signal
Active cluster sell — 13 distinct insiders, $13.1M, window ends Sep 14, 2026.
Figures computed from official regulatory filings — .
Analysttarget 22 USD (+23%) · consensus 5/5 · 3 buy · 0 hold · 0 sell
Ownershipinsiders 0.07% · institutions 3.31% · short 0.1% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for TAKEDA PHARMACEUTICAL CO LTD only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enantone, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, vyvanse/elvanse, Trintellix, and QDENGA brands. It has licensing and collaboration for the development and commercialization of products with Arrowhead Pharmaceuticals, Cour Pharmaceuticals, Engitix, Halozyme, Mirum Pharmaceuticals, Ucsd/Fortis Advisors, Zedira/Dr. Falk Pharma, Ac Immune, Acurastem, Anima Biotech, Biomarin, Denali Therapeutics, Luxna Biotech, Neurocrine Biosciences, Peptidream, Abbvie, Adimab, Ascentage Pharma, Crescendo Biologics, Exelixis, F-Star, Gsk, Heidelberg Pharma, Innovent Biologics, Keros Therapeutics, Kumquat Biosciences, Protagonist Therapeutics, Halozyme, Kamada, Johnson & Johnson/Momenta Pharmaceuticals, Previpharma, Novavax, Bridgene Biosciences, Charles River Laboratories, Iambic Therapeutics, Ipsen, Km Biologics, Massachusetts Institute Of Technology, and Nabla Bio. The company operates in Japan, the United States. Europe, Canada, Latin America, China, Asia, Russia/Commonwealth of Independent States, the Middle East, Oceania, and Africa. The company was founded in 1781 and is headquartered in Chuo, Japan.
Market information source · Oct 5, 2026
SEC company identity · Oct 5, 2026
Open-market timeline · full history
20 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Duprey Lauren Rusckowski | Sell | $640.3K | SEC |
| Plump Andrew Stewart | Sell | $2.1M | SEC |
| Plump Andrew Stewart | Sell | $363.3K | SEC |
| Greenway Nicola Deidre Petal | Sell | $235.1K | SEC |
| Bitetti Teresa Marie | Sell | $855.2K | SEC |
| Kim Julie So-Young | Sell | $1.5M | SEC |
| Ricci Gabriele | Sell | $429K | SEC |
| Ibrahim Ramy Riad Ahmed | Sell | $124.4K | SEC |
| Duprey Lauren Rusckowski | Sell | $813.7K | SEC |
| Platford Giles Richard | Sell | $531.5K | SEC |
| Shannon Elaine Mary | Sell | $68K | SEC |
| Greenway Nicola Deidre Petal | Sell | $115.8K | SEC |
| Pignagnoli Agosti Marcello | Sell | $392.6K | SEC |
| Greenway Nicola Deidre Petal | Sell | $588.7K | SEC |
| Shannon Elaine Mary | Sell | $357.4K | SEC |
| Plump Andrew Stewart | Sell | $2.8M | SEC |
| Pacheco Rhonda Janice | Sell | $289K | SEC |
| Greenway Nicola Deidre Petal | Sell | $17.1K | SEC |
| Furney Natalie Anne Marie | Sell | $527.8K | SEC |
| Farajallah Awny Samaan Botros | Sell | $239.5K | SEC |
| Furuta Milano | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Kim Julie So-Young | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Stoffels Paulus | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Tsusaka Miki | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Iijima Masami | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |